3688-23-1

Basic information

• Product Name: 2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol
• Synonyms: 2,3-Bis(3-methoxy-4-hydroxybenzyl)butane-1,4-diol;2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol
• CAS NO: 3688-23-1
• Molecular Formula: C₂₀H₂₆O₆
• Molecular Weight: 362.41684
• Mol File: 3688-23-1.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol(3688-23-1)
• EPA Substance Registry System: 2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol(3688-23-1)

Safety Data

• Hazardous Substances Data: 3688-23-1(Hazardous Substances Data)

Usage

General Description

2,3-Bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diol is a chemical compound that belongs to the class of butane diol derivatives. It is a synthetic compound with potential antioxidant and anti-inflammatory properties. This chemical has been studied for its potential applications in skincare and as a protective agent against oxidative stress. It is also being researched for its potential therapeutic effects in conditions related to inflammation and oxidative damage, although further studies are needed to fully understand its mechanisms and potential medical applications.

Upstream product

• 580-72-3 matairesinol 
• 111266-03-6 (R)-(+)-3-(4-benzyloxy-3-methoxybenzyl)-γ-butyrolactone 
• 60485-34-9 pinoresinol diglucoside 
• 190004-70-7 dimethyl 2,3-bis-(4-hydroxy-3-methoxybenzyl)succinate 
• 96917-15-6 (E)-2-(4'-benzyloxy-3'-methoxybenzylidene)succinic acid 
• 580-72-3 (2RS,3RS)-2,3-bis-(4-hydroxy-3-methoxybenzyl)butyrolactone 
• 487-36-5 (+/-)-pinoresinol 
• 1243054-22-9 trans-(E)-dimethyl 2,3-bis(4-benzyloxy-3-methoxybenzylidene)-1,4-butanediol 
• 1391062-42-2 C₂₁H₂₂O₆ 
• 190004-90-1 C₂₂H₂₂O₈ 
• 160097-43-8 C₂₁H₂₀O₈ 
• 190004-89-8 C₁₄H₁₆O₆ 
• 111194-03-7 C₁₃H₁₄O₆ 
• 888483-54-3 trans-(E)-2,3-bis(4'-benzyloxy-3'-methoxybenzylidene)succinic acid 

Downstream Products

• 121621-31-6 L_g-threo-1,4-bis-benzoyloxy-2,3-bis-(4-benzoyloxy-3-methoxy-benzyl)-butane 
• 67597-01-7 Secoisolarcinoltetraacetat 
• 580-72-3 (2RS,3RS)-2,3-bis-(4-hydroxy-3-methoxybenzyl)butyrolactone 
• 580-72-3 matairesinol 
• 119098-95-2 (-)-(2R,3R)-2-(3',4'-dihydroxybenzyl)-3-(3'',4''-dihydroxybenzyl)butyrolactone 
• 1206712-52-8 secoisolariciresinol-4',4''-diacetate 
• 3688-23-1 (-)-secoisolariciresinol 
• 145265-02-7 (-)-secoisolariciresinol 

Relevant articles and documents

Antiestrogenic and antiproliferative potency of secoisolariciresinol diglucoside derivatives on MCF-7 breast cancer cells

Secoisolariciresinol diglucoside (SDG) is isolated from Linum usitatissimum seeds. The antiproliferative effects of SDG (1) and its derivatives secoisolariciresinol (2) and secoisolariciresinol-4′, 4″-diacetate (3) have been evaluated on MCF-7 breast cancer cells and normal breast epithelial line MCF-10A. Lignan 1 has not shown cytotoxic effects on MCF-7 cells, while derivatives 2 and 3 have inhibited cell growth with IC50 values of 25 and 11 μM, respectively. Estrogen receptor alpha is a key growth driver in MCF-7 cells. Compound 1 did not affect the activity of ERα, while derivatives 2 and 3 showed significant antiestrogenic effects. Compounds 2 and 3 caused apoptosis in the MCF-7 line, determined by the cleavage of PARP. SDG derivative 3 enhanced the effect of doxorubicin. SDG derivatives can be considered as promising agents that exhibit a combined antiestrogen and proapoptotic effect in hormone-dependent breast cancer cells.

Total Synthesis and Stereochemical Confirmation of (-)-Olivil, (+)-Cycloolivil, (-)-Alashinols F and G, (+)-Cephafortin A, and Their Congeners: Filling in Biosynthetic Gaps

For the first time, we describe the stereocontrolled total syntheses of olivil, cephafortin A, 4-des-O-methyl-4-O-rhamnosyl cephafortin A, and alashinol F from a common precursor using a combination of chemoenzymatic and biomimetic methods for the systematic introduction of functional groups on three vicinal stereogenic carbon atoms. We revised the previously assigned stereochemistry of (+)-cephafortin A, which was reported as the enantiomer. Natural and unnatural congeners provide insights into the biogenetic interrelations of members of this family.

Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans

Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.